当前位置:首页 >财报库 > 报告详情

玛莱克琳生物技术公司Moleculin Biotech, Inc.(MBRX)美股招股说明书 S-1(2025-06-11修订版)(英文版)(57页).pdf

上传人: Y**** 编号:712900 2025-06-12 57页 1.14MB

下载:

1、S-1/A 1 mbrx20250606_s1a.htm FORM S-1/A Table of Contents As filed with the U.S.Securities and Exchange Commission on June 11,2025.Registration No.333-287727 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 AMENDMENT NO.2 TOFORM S-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF

2、1933 Moleculin Biotech,Inc.(Exact name of registrant as specified in its charter)Delaware283447-4671997(State or other jurisdiction of(Primary Standard Industrial(I.R.S.Employerincorporation or organization)Classification Code Number)Identification Number)5300 Memorial Drive,Suite 950Houston,Texas 7

3、7007(713)300-5160(Address,including zip code,and telephone number,including area code,of registrants principal executive offices)Walter V.Klemp,Chief Executive Officer and Chairman5300 Memorial Drive,Suite 950Houston,Texas 77007(713)300-5160(Name,address,including zip code,and telephone number,inclu

4、ding area code,of agent for service)Copies to:Cavas S.PavriJohnathan C.DuncanArentFox Schiff LLP1717 K Street NWWashington,DC 20006Telephone:(202)857-6000Fax:(202)857-6395Charles Phillips,Esq.Ellenoff Grossman&Schole LLP1345 Avenue of the Americas,11th FloorNew York,New York 10105Phone:(212)370-1300

5、 Approximate date of commencement of proposed sale to the public:As soon as practicable after the effective dateof this Registration Statement.If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant toRule 415 under the Securities Act of 193

6、3,check the following box.If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)under the Securities Act,please check the following box and list the Securities Act registration statement number of the earlier effective registration2025/6/12 08:55mbrx20250606_

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,全文主要概括如下: 1. Moleculin Biotech公司正在开展Annamycin药物的关键三期临床试验,用于治疗复发/难治急性髓细胞白血病。该试验预计将于2025年底进行中期揭盲,2026年上半年进行最终揭盲。 2. 公司拥有Annamycin、WP1066和WP1122三大技术平台,均源自MD安德森癌症中心。Annamycin已完成5项临床试验,未发现心脏毒性。WP1066和WP1122平台也在进行临床试验。 3. 本次发行最多1069万股普通股和3260万份认股权证,预计净融资680万美元,用于推进Annamycin和其他药物的临床开发,以及公司运营资金。 4. 公司股票在纳斯达克上市,代码为MBRX。本次发行无最低金额要求,可能存在融资不足风险。
安娜霉素的心脏毒性风险如何? 本次股票发行对投资者有何影响? 公司未来的资金需求将如何影响运营?
客服
商务合作
小程序
服务号
折叠